| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $275K | -93.2% | -79.1% |
| SG&A Expense | $213K | -58.6% | -83.8% |
| Operating Income | -$488K | +89.3% | +81.5% |
| Net Income | -$976K | +78.8% | +53.9% |
| EPS (Diluted) | -$0.11 | +80.0% | +84.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $0 | — | — |
| Current Assets | $663K | -2.5% | -77.1% |
| Total Assets | $690K | -7.5% | -76.7% |
| Current Liabilities | $8.7M | +10.4% | +157.3% |
| Total Liabilities | $8.7M | +10.0% | +136.4% |
| Stockholders' Equity | -$8.0M | -11.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.6M | — | — |
| Financing Cash Flow | $423K | — | — |
| -1024.2% |